Extended Dosing Interval for Somatuline Depot Injection Approved

The FDA has approved revised labeling to include an extended dosing interval of Somatuline Depot (lanreotide; Ipsen) Injection for the treatment of acromegaly. The updated dosing recommendations allow patients with acromegaly currently controlled on Somatuline Depot 60mg or 90mg every 4 weeks to be considered for an extended dosing interval of Somatuline Depot 120mg every 6 or 8 weeks.

Somatuline is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.

For more information visit www.ipsen.com/en.